Delta-Fly Pharma, Inc. (JP:4598)
:4598
Want to see JP:4598 full AI Analyst Report?
Top Page
Delta-Fly Pharma, Inc.
(4598)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥124.00
▼(-75.54% Downside)
Action:Upgraded
Date:06/13/26
Overall score is driven primarily by very weak financial performance (zero revenue in recent years, persistent large losses, heavy cash burn, and sharply reduced equity/assets), which raises funding and sustainability risk. Technical indicators also point to strong bearish momentum with the stock below all major moving averages and very low RSI/Stoch. Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
No financial leverage
A zero-debt capital structure is a durable strength: it lowers fixed obligations and refinancing risk, giving management flexibility to pursue R&D or partnerships without immediate interest burden. This structural cushion improves resilience when raising funds over the next 2–6 months.
Negative Factors
Zero recent revenue
Sustained zero revenue over multiple years is a structural weakness for long-term viability: it eliminates internally generated funding and forces dependency on external capital. For a development-stage biotech this raises execution and funding risk until commercialization or major licensing occurs.
Read all positive and negative factors
Positive Factors
Negative Factors
No financial leverage
A zero-debt capital structure is a durable strength: it lowers fixed obligations and refinancing risk, giving management flexibility to pursue R&D or partnerships without immediate interest burden. This structural cushion improves resilience when raising funds over the next 2–6 months.
Read all positive factors
Delta-Fly Pharma, Inc. (4598) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.82B
Dividend YieldN/A
Average Volume (3M)379.72K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue GrowthN/A
EPS Growth28.49%
CountryJP
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-171.79
Shares Outstanding14,225,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Delta-Fly Pharma, Inc. Business Overview & Revenue Model
Company Description
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-1091...
How the Company Makes Money
Delta-Fly Pharma, Inc. generates revenue primarily through the development and eventual commercialization of its oncology drug portfolio. The company may earn income through licensing agreements, partnerships with larger pharmaceutical firms, and ...
Delta-Fly Pharma, Inc. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00M |
| Gross Profit | -1.55M | -1.44M | -1.59M | -1.51M | -1.63M | 300.00M |
| EBITDA | -1.57B | -1.60B | -1.71B | -1.40B | -1.31B | -959.79M |
| Net Income | -1.59B | -1.63B | -1.72B | -1.43B | -1.33B | -967.30M |
Balance Sheet | ||||||
| Total Assets | 790.57M | 246.67M | 434.33M | 1.47B | 906.82M | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 730.32M | 145.45M | 338.83M | 1.42B | 844.34M | 1.27B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 137.03M | 212.69M | 156.54M | 241.50M | 115.62M | 91.19M |
| Stockholders Equity | 653.55M | 33.98M | 277.80M | 1.23B | 791.20M | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.56B | -1.83B | -1.28B | -1.30B | -940.40M |
| Operating Cash Flow | 0.00 | -1.56B | -1.83B | -1.28B | -1.30B | -940.40M |
| Investing Cash Flow | 0.00 | 0.00 | -206.00K | 207.00K | -326.00K | 0.00 |
| Financing Cash Flow | 0.00 | 1.36B | 756.70M | 1.85B | 882.62M | 119.86M |
Delta-Fly Pharma, Inc. Technical Analysis
Negative
507.00
Price Trends
173.18
Negative
198.82
Negative
354.71
Negative
Market Momentum
-13.75
Negative
25.30
Positive
13.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4598, the sentiment is Negative. The current price of 507 is above the 20-day moving average (MA) of 144.10, above the 50-day MA of 173.18, and above the 200-day MA of 354.71, indicating a bearish trend. The MACD of -13.75 indicates Negative momentum. The RSI at 25.30 is Positive, neither overbought nor oversold. The STOCH value of 13.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4598.
Delta-Fly Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥18.75B | -3.75 | -184.71% | ― | 29.94% | 86.03% | |
47 Neutral | ¥81.50B | -49.50 | ― | ― | 0.80% | 32.87% | |
45 Neutral | ¥3.53B | -2.92 | ― | ― | 42.38% | 8.81% | |
41 Neutral | ¥1.82B | -1.00 | ― | ― | ― | 28.49% | |
41 Neutral | ¥132.29B | -36.31 | -10.16% | ― | -59.19% | -124.16% | |
41 Neutral | ¥86.10B | -27.20 | -253.07% | ― | ― | 31.36% |
* Healthcare Sector Average
JP:4598
Delta-Fly Pharma, Inc.
122.00
-510.00
-80.70%
JP:4563
AnGes
48.00
-16.00
-25.00%
JP:4587
Peptidream
959.80
-673.20
-41.22%
JP:4592
SanBio Co
1,022.00
-1,719.00
-62.71%
JP:4588
Oncolys BioPharma, Inc.
2,591.00
1,979.00
323.37%
JP:4591
Ribomic, Inc.
61.00
-41.00
-40.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.